• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗的心肌血运重建:过去、现在和未来。

Myocardial revascularization by percutaneous coronary intervention: past, present, and the future.

出版信息

Curr Probl Cardiol. 2011 Oct;36(10):375-401. doi: 10.1016/j.cpcardiol.2011.05.005.

DOI:10.1016/j.cpcardiol.2011.05.005
PMID:21889660
Abstract

Percutaneous coronary revascularization was introduced over 30 years ago by Dr Andreas Grüntzig. This event catapulted adult invasive cardiology from a diagnostic entity to a therapeutic modality, which has since become the most frequently performed coronary revascularization procedure worldwide. This success has been built on several key concepts-problem identification, targeted solutions, applied technology, populations-based testing, postmarket surveillance, and education. These concepts will continue to be of paramount importance as novel percutaneous innovations and strategies are brought to bear on an increasingly broader group of patients with cardiovascular disease. In this review, we trace the history, review current practices, and also provide insight into future potential innovations, as it pertains to percutaneous coronary revascularization.

摘要

经皮冠状动脉血运重建术由 Andreas Grüntzig 博士于 30 多年前首创。这一事件将成人介入心脏病学从一个诊断实体推向了治疗模式,自此成为全球最常进行的冠状动脉血运重建术。这一成功基于几个关键概念,包括问题识别、靶向解决方案、应用技术、基于人群的测试、上市后监测和教育。随着新型经皮创新和策略应用于越来越广泛的心血管疾病患者群体,这些概念将继续至关重要。在这篇综述中,我们追溯了经皮冠状动脉血运重建术的历史,回顾了当前的实践,并对未来的潜在创新提供了深入了解。

相似文献

1
Myocardial revascularization by percutaneous coronary intervention: past, present, and the future.经皮冠状动脉介入治疗的心肌血运重建:过去、现在和未来。
Curr Probl Cardiol. 2011 Oct;36(10):375-401. doi: 10.1016/j.cpcardiol.2011.05.005.
2
A perspective on the development of coronary revascularization.冠状动脉血运重建发展的展望。
Coron Artery Dis. 2010 May;21(3):199-203. doi: 10.1097/MCA.0b013e328337cf78.
3
Catheter-based treatment of coronary artery disease: past, present, and future.基于导管的冠状动脉疾病治疗:过去、现在和未来。
Circ Cardiovasc Interv. 2008 Aug;1(1):60-73. doi: 10.1161/CIRCINTERVENTIONS.108.783134.
4
[Coronary angioplasty in elderly patients].[老年患者的冠状动脉血管成形术]
Ital Heart J Suppl. 2002 Jan;3(1):1-8.
5
[Myocardial revascularization in the early XXIst century: less and less bypass indications].[21世纪初的心肌血运重建:搭桥适应症越来越少]
Presse Med. 2008 Nov;37(11):1575-9. doi: 10.1016/j.lpm.2008.03.012. Epub 2008 Sep 10.
6
Hybrid coronary revascularization: which patients? When? How?杂交冠状动脉血运重建:哪些患者?何时?如何?
Curr Opin Cardiol. 2010 Nov;25(6):568-74. doi: 10.1097/HCO.0b013e32833f02fb.
7
API expert consensus document on management of ischemic heart disease.缺血性心脏病管理的API专家共识文件
J Assoc Physicians India. 2006 Jun;54:469-80.
8
[Clinical decision making in left main coronary artery disease revascularization: the past, present and future].[左主干冠状动脉疾病血运重建的临床决策:过去、现在与未来]
Recenti Prog Med. 2012 Mar;103(3):119-27. doi: 10.1701/1046.11403.
9
ABC of interventional cardiology: percutaneous coronary intervention. I: history and development.介入心脏病学基础:经皮冠状动脉介入治疗。I:历史与发展
BMJ. 2003 May 17;326(7398):1080-2. doi: 10.1136/bmj.326.7398.1080.
10
Evolution and future perspectives for cardiovascular interventions in China.中国心血管介入治疗的发展历程与未来展望
EuroIntervention. 2012 Nov 22;8(7):773-8. doi: 10.4244/EIJV8I7A119.

引用本文的文献

1
Impact of prior permanent pacemaker on long-term clinical outcomes of patients undergoing percutaneous coronary intervention.既往永久性起搏器对接受经皮冠状动脉介入治疗患者长期临床结局的影响。
Clin Cardiol. 2017 Apr;40(4):205-209. doi: 10.1002/clc.22645. Epub 2016 Nov 23.
2
Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention.通心络胶囊用于经皮冠状动脉介入治疗后的冠心病患者。
Cochrane Database Syst Rev. 2015 May 21;2015(5):CD010237. doi: 10.1002/14651858.CD010237.pub2.
3
Integrin αIIbβ3: from discovery to efficacious therapeutic target.
整合素 αIIbβ3:从发现到有效的治疗靶点。
Circ Res. 2013 Apr 12;112(8):1189-200. doi: 10.1161/CIRCRESAHA.112.300570.